Incidence and risk factors for liver enzyme elevation during 1 highly active antiretroviral therapy in HIV - HCV co - infected patients : 2 results from the Italian EPOKA - MASTER Cohort 3 4
نویسندگان
چکیده
1 2 Background: The risk of hepatotoxicity associated with different highly active 3 antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, 4 single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV5 HCV co-infected patients has not been fully assessed. 6 Methods: Retrospective analysis of a prospective cohort of 1,038 HIV-HCV co7 infected patients who commenced a new HAART in the Italian MASTER database. 8 Patients were stratified into naïve and experienced to antiretroviral therapy before 9 starting the study regimens. Time to grade ≥III hepatotoxicity was the primary outcome. 10 Secondary outcome was time to grade IV hepatotoxicity. 11 Results: Incidence of grade ≥III hepatotoxicity was 17.71 per 100 patient-years (p-yr) 12 of follow up in naïve patient group and 8.22 per 100 p-yrs in experienced group (grade 13 IV: 4.13 per 100 p-yrs and 1.08 per 100 p-yrs, respectively). In the latter group, the only 14 independent factors associated with shorter time to the event at proportional hazard 15 regression model were: previous liver transaminase elevations to grade >III, higher 16 baseline alanine amino-transferase values, and use of a non nucleoside reverse 17 transcriptase inhibitor based regimen. In the naive group, baseline aspartate 18 transaminase level was associated with the primary outcome. 19 Conclusions: Use of a single or multiple PI-based regimen was not associated with risk 20 of hepatotoxicity in either naïve or experienced patient groups. A cautious approach 21 with strict monitoring should be applied in HIV-HCV co-infected experienced patients 22 with previous liver transaminase elevations, higher baseline alanine amino-transferase 23
منابع مشابه
Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
BACKGROUND The risk of hepatotoxicity associated with different highly active antiretroviral therapy (HAART) regimens (containing multiple-protease inhibitors, single-protease inhibitors or non nucleoside reverse transcriptase inhibitors) in HIV-HCV co-infected patients has not been fully assessed. METHODS Retrospective analysis of a prospective cohort of 1,038 HIV-HCV co-infected patients wh...
متن کاملIncidence and risk factors for liver enzyme elevation during antiretroviral therapy in HIV/HCV coinfected patients RUNNING HEAD: Hepatotoxicity in HIV/HCV coinfection
Background: The risk of hepatotoxicity associated with different HAART regimens (multiple-PI, single-PI or NNRTI-based) in HCV co-infected patients has not been fully assessed. Methods: Retrospective analysis of a prospective cohort of 1,038 HIV/HCV coinfected patients who commenced a new HAART in the Italian MASTER database. Patients were stratified into naïve (N) and experienced (E) to antire...
متن کاملGrade 3-4 liver enzyme elevation during HAART in HIV and hepatitis C co-infected adults.
AIM To evaluate the incidence of grade 3-4 LEE in HIV/HCV co-infected patients after the introduction of HAART, the clinical significance to the patients and to determine any factors that could predict its development. METHODS A retrospective cohort study of HIV/HCV co-infected adults in Pokdisus AIDS Clinic Cipto Mangunkusumo Hospital was conducted. All patients were antiretroviral naive and...
متن کاملMetabolic Abnormalities in HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly activ...
متن کاملLiver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.
Background The principal causes of liver enzyme elevation among HIV-hepatitis B virus (HBV) co-infected patients are the hepatotoxic effects of antiretroviral therapy (ART), alcohol abuse, ART-induced immune reconstitution and the exacerbation of chronic HBV infection. Objectives To investigate the incidence and severity of liver enzyme elevation, liver failure and death following lamivudine (3...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005